Category: Stock Market

The Ampol Ltd (ASX: ALD) share price is in focus after the company posted an 83% jump in RCOP NPAT to $429 million for FY 2025, alongside a fully franked final dividend of 60 cents per share.

What did Ampol report?

• Group RCOP EBITDA up 20% to $1.44 billion
• RCOP Net Profit After Tax (NPAT) rose 83% to $429 million
• Statutory NPAT of $82.4 million, down 33% year on year
• Full year fully franked dividends totalled 100 cents per share
• Leverage ratio at 2.3x Adjusted Net Debt/RCOP EBITDA
• Convenience Retail, Fuels and Infrastructure, and New Zealand all delivered earnings growth

What else do investors need to know?

Ampol made progress on several strategic priorities, including continuing to work towards its proposed acquisition of EG Australia, with completion expected mid-year subject to regulatory approval. The sale of interests in Channel Infrastructure and a divestment from electricity retailing have bolstered the company’s balance sheet.

In Convenience Retail, network shop sales (excluding tobacco and U-GO conversions) grew 2.8%, supported by higher margins from the QSR, beverages, and bakery categories. Ampol continued to shift away from tobacco, which now represents a smaller share of overall sales and margins.

The Fuels and Infrastructure segment benefited from a strong rebound in Lytton refinery performance, with production up to 5.5 billion litres for the year and significantly improved refining margins compared to FY 2024.

What did Ampol management say?

Managing Director and CEO Matt Halliday said:

The financial performance in 2025 is a high quality and broad-based result that reflects the steps taken in recent years to strengthen our delivery and increase our exposure to the more stable and growing business segments. The 5-year compound annual growth rate of the combined EBIT from these businesses is about 11 per cent including the contribution through the acquisition of Z Energy.

What’s next for Ampol?

Ampol enters 2026 with positive momentum, especially in Convenience Retail and New Zealand, thanks to continued store execution and favourable retail margins. The company is engaging with government on the Fuel Security Services Payment review and advancing expansion projects such as the Ultra Low Sulfur Fuels project, which is targeted to commence commissioning in the second quarter.

The proposed EG Australia acquisition remains a strategic focus, with the competition regulator’s decision expected in June 2026. Ampol is confident in its ability to deliver on its investment and growth goals, leveraging its strong retail platforms and integrated supply chain.

Ampol share price snapshot

Over the past 12 months, Ampol shares have risen 6% trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Ampol FY25 earnings: profit jumps and dividend up appeared first on The Motley Fool Australia.

More reading

• Stanmore Resources FY25 earnings: Record output
• West African Resources provides Burkina Faso government stake update
• Greatland Resources earnings: Bumper profit and revenue after first full Telfer half
• Regis Healthcare grows revenue and cash flow in H1 FY26 earnings
• Lendlease half-year results: $318m loss, construction steady, capital recycling on track

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Guzman Y Gomez Ltd (ASX: GYG) share price is an attractive opportunity after its latest result, according to the broker UBS.

The Mexican food business saw a share price 14% decline after its result, despite reporting a solid level of growth.

It reported that 14 more Australian restaurants were opened during the six-month period, helping network sales grow 18% to $681.8 million. Guzman Y Gomez’s revenue increased 23% to $261.2 million, operating profit (EBITDA) climbed 29.6% to $40.9 million and net profit after tax (NPAT) increased 44.9% to $10.6 million.

The business decided to declare an interim dividend per share of 7.4 cents

After seeing those numbers, there were a few reasons why UBS upgraded its view on the Guzman Y Gomez share price.

Strong growth outlook in Australia and the US

UBS says that GYG has “a very attractive growth outlook in Australia with multiple drivers”.

Firstly, it’s delivered mid-single-digit same-store sales (SSS) growth driven by menu innovation, customers visiting at more times of the day, renewed delivery growth and longer opening hours. The broker noted that the Mexican food business is investing in its systems to enable the rush to be handled.

Next, the company has significant restaurant network growth, which is forecast to grow from 224 in FY25 to more than 400 in FY30 and more than 600 in FY35 as it reaches towards a long-term ambition of 1,000 restaurants. The network growth is being enabled by investing in its property team and attractive franchisee store financials (with the median franchisee return on investment (ROI) being 48%).

Third, the operating profit (EBITDA) margin is expected to grow from 5.7% in FY26, to between 6% to 6.2% in FY26 and then grow towards 10% in the early 2030s. This is expected to be driven by a rising franchisee royalty rate, a lower general and administration (to sales) ratio and higher corporate restaurant margins. This could be a good tailwind for the Guzman Y Gomez share price.

The US opportunity is also interesting and currently has eight locations. It’s expected to see a larger loss in FY26, which is gaining investor attention. But, GYG notes that customers are “positive” on the brand and food quality, as they were in Australia, though brand building is difficult and SSS growth has been “modest”.

UBS points out that the US quick service restaurant (QSR) market is the largest globally and therefore attractive, though execution risk is high. The broker forecasts that the US average unit value (AUV) per restaurant could reach US$3 million by FY31, which is the “key requirement” to reach breakeven in the US and grow beyond its initial limit of 15.

Guzman Y Gomez share price valuation

Discussing the valuation, UBS wrote:

The valuation is more attractive following share price performance since Jan25 (-57%, vs XSO +19%) and the FY25 result (-26%, vs XSO +5%). GYG is trading at a FY26 EV/EBITDA (adj. – pre AASB2 & AASB16) multiple of 23x (including the loss-making US business) based on FactSet (consensus); this is below other high growth QSRs.

Based on the UBS profit forecast for the 2027 financial year, it’s valued at 57x FY27’s estimated earnings. UBS has a price target of $21 on the business, implying a possible rise of around 20% over the next year, at the time of writing.

The post Why UBS just upgraded Guzman Y Gomez shares to a buy appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Why Guzman Y Gomez, Inghams, Megaport, and Rio Tinto shares are tumbling today
• Guzman y Gomez shares crash to a record low following half-year results
• Guzman y Gomez posts 1H26 earnings
• Are these ASX shares too cheap to pass up?

Motley Fool contributor Tristan Harrison has positions in Guzman Y Gomez. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CLS) shares have lost 42% in value over 12 months and 12% in 2026.  

The global biotech heavyweight — once a market darling — is in a rough stretch. Earlier this month, the ASX biotech posted disappointing half-year results, and CEO transition noise has only added to the pressure.

Investors might want to shift their focus to a smaller rival of CSL shares: Telix Pharmaceuticals Ltd (ASX: TLX). It finished last week with a 14% rise to $10.43.

More importantly, brokers tip explosive upside for this ASX share. Let’s find out why.

Big ups and downs

Telix Pharmaceuticals delivered standout gains over the past 12 months, climbing to a peak of $31.97 nearly a year ago. Since then, it has tumbled 67% to $10.43 at the time of writing.

Telix develops radiopharmaceuticals for cancer diagnosis and treatment, combining biotech innovation with specialised manufacturing and global distribution.

Crucially, Telix has moved beyond the development stage and into full commercial operations. As regulatory approvals convert into wider clinical adoption, revenue can scale rapidly.

The growth of the competitor of CSL shares now depends on product uptake and market penetration rather than economic cycles. That dynamic introduces volatility, but it also gives investors direct exposure to a healthcare niche where innovation can translate quickly into earnings.

Turnover exceeding $1 billion

On Friday Telix reported a huge jump in full-year revenues while also saying it expects to easily beat that amount in the current year.

The drug company said in a statement to the ASX on Friday that full-year revenue had come in at US$803 million, up 56% year on year, and at the lower end of its upsized guidance range of US$800 to US$820 million.

Telix also provided guidance for the current year, saying it expected to turn over US$950 to US$970 million ($1.35 to $1.38 billion), while the company would spend US$200 to US$240 million on research and development.

Urgent need, no competition

Last week, the company announced it has submitted a European marketing authorisation application for TLX101-Px, its brain cancer imaging agent.

TLX101-Px is set to play a key role in Telix’s glioblastoma therapy program, helping clinicians select and monitor patients in ongoing trials — including phase 3 studies in Europe.

Importantly, there are no widely available commercial alternatives. That leaves Telix well placed to meet an urgent clinical need with little to no direct competition.

What next for Telix and CSL shares?

Telix still has exceptional growth potential in a rapidly expanding market, and at its current share price, the ASX stock is highly attractive. Analysts are overwhelmingly bullish on Telix heading into 2026.

According to TradingView, all 15 analysts covering the stock rate it a Buy or Strong Buy — a rare show of unanimity — and they expect significant upside over the next year.

Price targets are aggressive. The consensus suggests the shares could surge 139% to $24.94. The most optimistic forecasts go even further, projecting a rise to $32.30 per share. This points to a staggering 210% upside from current levels, more than tripling the stock’s present value.

By comparison, Bell Potter just cut its 12-month price target for CSL shares from $195 to $175. This suggests a modest 13% upside at current levels for the $74 billion ASX share.

The post Forget CSL shares, this ASX biotech stock could triple in value appeared first on The Motley Fool Australia.

More reading

• Why Telix shares could rise 80% in a year
• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today
• This biotech says it will turn over more than $1 billion next year. Is it undervalued?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Telix Pharmaceuticals. The Motley Fool Australia has recommended CSL and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Greatland Resources Ltd (ASX: GGP) share price is in focus today as the gold and copper miner reported half-year revenue of $977.3 million and net profit after tax of $342.9 million, both significantly higher than the prior period.

What did Greatland Resources report?

• Revenue from ordinary activities surged to $977.3 million, up 5,797% from $16.6 million a year earlier
• Net profit after tax rose to $342.9 million, an 876% increase from $35.1 million in the previous corresponding period
• EBITDA soared to $560.3 million (from $10.8 million)
• Free cash flow grew to $387.4 million (compared to a $280.9 million outflow last year)
• Net tangible assets per share lifted to $2.47, representing a 24% improvement
• No interim dividend declared for the half year

What else do investors need to know?

Greatland completed its first full reporting period with 100% ownership of the Telfer gold-copper mine, which produced 167,163 ounces of gold and 6,894 tonnes of copper at an all-in sustaining cost of $2,176/oz. Operational improvements included upgrades to processing facilities, grade control systems, and open pit fleet renewals to lift productivity and safety metrics.

The company continued investment in growth, spending $177 million during the half, split across expansion at Telfer, feasibility work and early works at the world-class Havieron gold-copper development project, and resource drilling. The Havieron Feasibility Study, completed in December 2025, confirmed a clear path to a long-life, low-cost operation leveraging Telfer’s infrastructure.

Greatland advanced regional exploration, including new drilling at the Paterson South project, where it formed a joint venture with Rio Tinto Exploration. The company also secured binding commitments for $500 million in new corporate debt facilities to support project development and working capital.

What’s next for Greatland Resources?

Looking ahead, Greatland aims to maintain strong production at Telfer while progressing the Havieron mine towards development. The company is targeting environmental approvals and a final investment decision on Havieron in FY26, with first gold expected about 2.5 years post-approval.

Greatland plans to integrate low-grade stockpiles into mine schedules, continue the open pit fleet renewal, and advance resource drilling. The new debt facilities, alongside robust cash flows, are expected to provide ample funding flexibility for both Telfer’s ongoing needs and the upcoming Havieron build.

Greatland Resources share price snapshot

Over the past 12 months, Greatland Resources shares have risen 78%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Greatland Resources earnings: Bumper profit and revenue after first full Telfer half appeared first on The Motley Fool Australia.

More reading

• Regis Healthcare grows revenue and cash flow in H1 FY26 earnings
• Lendlease half-year results: $318m loss, construction steady, capital recycling on track
• nib Group lifts 1H26 profit, keeps dividend steady
• Reece HY26 results: Profit falls despite higher sales revenue
• Chorus half-year earnings: Profit growth and higher fibre uptake

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Can you retire in 10 years?

For many Australians in their mid-50s, that question feels uncomfortably close to home. The numbers tell an important story.

According to recent data, the average superannuation balance for Australians aged 55 sits well below what most experts consider necessary for a “comfortable” retirement at 65. Meanwhile, industry benchmarks suggest a couple retiring at 65 may need well over $600,000 in super to fund a comfortable lifestyle, depending on spending expectations and eligibility for the Age Pension.

That gap is the simple number most Australians miss.

It is not just about how much you have today. It is about how much your capital can grow over the next decade.

The 10-year compounding window

Over the past 30 years, the Australian share market has delivered average annual returns of around 9.3%, including dividends. That does not mean markets rise by 9.3% every year. Some years are strong, others are deeply negative. However, over long periods, that average has held remarkably steady.

If you are 55 today and planning to retire at 65, you still have a full decade for your capital to compound.

For example, a $400,000 super balance growing at an average rate close to long-term market returns could look very different after 10 years of compounding. Even modest additional contributions during this period can meaningfully lift the final balance.

The key insight is this: the last 10 years before retirement are not a time when growth stops mattering. In many cases, they matter most.

The sequencing risk trap

There is, however, a major risk that often goes overlooked.

It is known as sequencing risk.

This refers to the danger of experiencing poor market returns in the years immediately before or after retirement. A sharp downturn just as you begin drawing income can have a disproportionate impact on how long your capital lasts.

This is why many investors think carefully about how they transition from growth to income. It is rarely an all-or-nothing decision.

Strategies such as dollar-cost averaging, where investments are made progressively over time rather than in one lump sum, are often discussed as a way to smooth out entry points and reduce the impact of short-term volatility. While no strategy removes market risk entirely, spreading investments over time can help investors navigate the natural ups and downs of markets and potentially stay closer to long-term average returns.

Growth first, income second

One of the most common mistakes is focusing too early on income and yield, especially when retirement is still years away.

For many Australians at 55, the priority over the next decade may still be capital growth. As retirement approaches, portfolios can gradually shift toward more income-oriented assets, depending on personal circumstances, risk tolerance, and access to other income sources.

The simple number that matters is not just your current super balance.

It is the number you are likely to have at 65.

That difference depends on three things:

• Your starting balance
• Your contribution rate over the next decade
• Your average return over that period

Retirement in 10 years is not simply about cutting spending or hoping the Age Pension fills the gap. It is about making deliberate decisions during what could be the most powerful compounding phase of your financial life.

For Australians approaching their mid-50s, the question is not whether retirement is close.

It is whether the next 10 years are being used wisely.

The post Is your superannuation investing on track to retire in 10 years? appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares, this ASX biotech stock could triple in value
• Greatland Resources earnings: Bumper profit and revenue after first full Telfer half
• Here’s a $50,000 starter dividend portfolio delivering passive income
• Why this growing ASX 200 gold stock could rise 40%
• Regis Healthcare grows revenue and cash flow in H1 FY26 earnings

Motley Fool contributor Leigh Gant has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Building passive income from ASX shares does not require a six-figure portfolio.

In fact, $50,000 is enough to lay the foundations of a simple dividend strategy that blends growth with income. The key is balance. Chasing the highest yield alone can expose investors to unnecessary risk, while focusing only on growth may delay income generation.

A blended approach using exchange-traded funds could provide both.

Step one: diversify exposure to dividends and growth

One way to structure a starter portfolio is to split it into two parts. The first part focuses on broad market exposure.

For example, an ETF tracking the the top Australian businesses such as the Vanguard Australian Shares Index ETF (ASX: VAS) provides exposure to many of Australia’s largest dividend-paying companies. Banks, miners, healthcare leaders, and industrials all sit inside the index. Over time, this gives investors access to both capital growth and dividend income.

Pairing that with an S&P 500 ETF, like iShares S&P 500 AUD ETF (ASX: IVV) adds global exposure. The US market includes world-leading companies across technology, consumer goods, and financial services. While US dividend yields are typically lower than Australia’s, the long-term growth profile has historically been strong.

An illustrative allocation might look like:

• $20,000 in an ASX 300 ETF
• $15,000 in an S&P 500 ETF

This portion of the portfolio focuses on broad diversification and long-term capital growth. Dividends are part of the return, but not the only driver.

Step two: dedicated dividend exposure

he second portion of the portfolio can lean more deliberately toward income.

One way investors do this is by allocating capital to high dividend yield ETFs. For example, Vanguard Australian Shares High Yield ETF (ASX: VHY) focuses on Australian companies with comparatively higher forecast dividend yields. The portfolio typically includes large, established businesses such as BHP Group Ltd (ASX: BHP) and Commonwealth Bank of Australia (ASX: CBA), while still applying diversification rules to avoid being overly concentrated in one sector.

High yield exposure can lift the portfolio’s overall income profile. However, it also means being mindful of sector bias. Australian dividend ETFs often have heavier exposure to banks and resources, which can introduce cyclical risk.

To complement this, some investors consider adding an income-focused bond ETF such as VanEck Emerging Income Opportunities Active ETF (ASX: EBND).

Bond income behaves differently from share dividends. Instead of relying on corporate profits, it is driven by interest payments from fixed-income securities. While emerging market bonds carry their own risks, including currency and credit risk, they can provide an alternative income stream that is not directly tied to share market performance.

For a starter passive income portfolio, that difference matters. If equity markets experience volatility, bond income may help smooth overall returns and reduce reliance on dividend payments alone.

An illustrative allocation for the income sleeve could look like:

• $10,000 in a high dividend yield ETF
• $5,000 in a bond income ETF

The compounding effect matters

The real power of a starter dividend portfolio lies in reinvestment.

If dividends are reinvested and the portfolio continues to grow through additional contributions, the income stream can expand over time. Australian shares have historically delivered long-term returns that combine both price appreciation and dividends, and reinvested income has been a major driver of total return.

A $50,000 portfolio generating income today could look very different in a decade if contributions and compounding continue.

Income and growth do not need to be opposites

One of the biggest misconceptions about dividend investing is that investors must choose between income and growth.

A blended ETF approach allows for both.

Broad market exposure provides participation in Australia’s and the United States’ largest companies. Dedicated dividend ETFs can tilt the portfolio toward higher income.

For investors starting with $50,000, the goal may not be to replace a salary immediately. Instead, it may be to build a structured, diversified foundation that can grow alongside an expanding passive income stream over time.

The post Here’s a $50,000 starter dividend portfolio delivering passive income appeared first on The Motley Fool Australia.

More reading

• Why I’d buy and hold these 5 ASX 200 shares until 2036
• I think these Vanguard ETFs are standout buys today
• 2 more ASX 200 blue chip stocks that increased dividends this week
• 5 low-cost ASX ETFs for a global diversified portfolio
• How to build an ASX share portfolio you can stick with long term

Motley Fool contributor Leigh Gant has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended iShares S&P 500 ETF. The Motley Fool Australia has recommended BHP Group, Vanguard Australian Shares High Yield ETF, and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are wanting exposure to the gold industry, then it could be worth considering the ASX 200 gold stock in this article.

That’s because if Bell Potter is on the money with its recommendation, this gold miner’s shares could provide big returns over the next 12 months.

Which ASX 200 gold stock?

The gold stock that Bell Potter is bullish on is Genesis Minerals Ltd (ASX: GMD). It is a gold miner focused on the prolific Leonora District in Western Australia.

Bell Potter was pleased with its half-year results, noting that its revenue and earnings were largely in line with expectations. It said:

Highlights of GMD’s 1HFY26 financial result include: Revenue of A$820m, a 142% increase vs PcP (BPe A$814m & VA A$814m); COGS were A$371m, an 85% increase vs PcP, as production ramped up across the two production centres. Costs were mildly ahead of our estimates and consensus after adjusting for depreciation and amortisation; EBITDA in the first half was A$430m (BPe A$441m, VA A$430m). NPAT was A$238m, a 4x increase on the PcP of $59.8m, driven by a higher achieved gold price and increased production. The result was largely in line with our estimate and ~2% below consensus.

The other big news is that the ASX 200 gold stock has signed an agreement to acquire Magnetic Resources NL (ASX: MAU) for $639 million. Bell Potter points out that this deal puts the company on a production pathway to 500,000 ounces per annum. This compares to its current guidance for FY 2026 of 260,000 ounces to 290,000 ounces. The broker said:

The acquisition adds 2.2Moz in Resources (acquisition cost A$290/oz Resource). The acquisition brings potentially higher-grade inventories into the Laverton mill (~20km away), helping lift production and supplementing lower grade ounces from Jupiter. The long-term growth guidance update has been pushed back, with management now targeting 1QFY27 (previously 2HFY26). A statement was made on mill expansion capacity targets of between 3.5-4.0Mtpa at Tower Hill, whether this supplements the existing Leonora mill (1.4Mtpa) or replaces it is uncertain.

Time to buy

According to the note, the broker has retained its buy rating and $9.90 price target on the ASX 200 gold stock.

Based on its current share price of $6.87, this implies potential upside of 44% for investors over the next 12 months.

Commenting on its buy recommendation, Bell Potter said:

We maintain our TP of $9.90 and Buy recommendation. We believe GMD to be a high-quality gold producer, expanding production underpinned by a large Mineral Resource portfolio (21.0Moz pending completion of MAU transaction), into a rising gold price environment.

The post Why this growing ASX 200 gold stock could rise 40% appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Why A2 Milk, Aurizon, JB Hi-Fi, and Magnetic Resources shares are storming higher today
• Genesis Minerals lobs takeover bid for Magnetic Resources
• UBS raises gold price target to US$6,200 per ounce for this quarter
• Four mining stocks to watch ahead of reporting season

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Regis Healthcare Ltd (ASX: REG) share price is in focus after the company delivered an 18% lift in revenue in its H1 FY26 result.

What did Regis Healthcare report?

• Revenue from services grew 18% to $667.7 million.
• Underlying EBITDA increased 4% to $70.6 million.
• Underlying NPAT edged up 0.1% to $29.7 million, while statutory NPAT fell to $13.4 million due to one-off costs.
• Net operating cash flow jumped 40% to $291.7 million.
• Interim dividend of 9.0 cents per share (100% franked), payable 9 April 2026.
• Net cash position improved 10% to $198.0 million.

What else do investors need to know?

Regis reported mature homes average occupancy of 96.0%, with total occupied bed days rising 7%. The company benefited from increased government funding, improved room pricing, and recent acquisitions, which expanded its national portfolio by over 1,000 beds.

Several one-off expenses, including $12.8 million in acquisition and integration costs, impacted statutory profits. Capital expenditure reached $102.1 million, focused on acquisitions, property upgrades, and progressing greenfield developments at Toowong and Carlingford.

Staff levels increased to meet mandated care targets, while staff turnover dropped to 20.2%. The acquisitions of Rockpool and OC Health have been integrated and are expected to contribute positively in future periods.

What did Regis Healthcare management say?

Managing Director and CEO Dr Linda Mellors said:

Our half-year results demonstrate the resilience and momentum of the business as we continue to operate in a rapidly evolving operating environment. We remain focused on delivering high-quality care while advancing our growth strategy, supported by high occupancy and continued investment in our people and service offering. Revenue growth was driven by higher AN-ACC pricing, improved occupancy, and the recent acquisitions of Ti Tree Operations Pty Ltd (Ti Tree), Rockpool and OC Health, collectively adding eight homes and over 1,000 beds to our national portfolio. We also delivered an exceptional cashflow result, driven by increased net RAD cash inflows, reinforcing the strength of our market position.

What’s next for Regis Healthcare?

Regis is targeting growth to 10,000 quality beds by FY28, through a mix of greenfield projects and acquisitions. An active development pipeline is expected to add 300–450 beds from new builds by FY28, with the remainder from M&A.

The company expects continued benefits from aged care funding reforms and demographic shifts. It is guiding to FY26 underlying EBITDA in the range of $130 million to $135 million as it executes its growth strategy, supported by a strong balance sheet.

Regis Healthcare share price snapshot

Over the past 12 months, Regis Healthcare shares have risen 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Regis Healthcare grows revenue and cash flow in H1 FY26 earnings appeared first on The Motley Fool Australia.

More reading

• Greatland Resources earnings: Bumper profit and revenue after first full Telfer half
• Lendlease half-year results: $318m loss, construction steady, capital recycling on track
• nib Group lifts 1H26 profit, keeps dividend steady
• Reece HY26 results: Profit falls despite higher sales revenue
• Chorus half-year earnings: Profit growth and higher fibre uptake

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Telix Pharmaceuticals Ltd (ASX: TLX) shares have had a tough time over the past 12 months.

During this time, the radiopharmaceuticals company’s shares have lost 65% of their value.

While this is disappointing, Bell Potter believes that it could have created a compelling buying opportunity for investors.

What is the broker saying?

Bell Potter notes that Telix has released its half-year results this month and reported a drop in earnings. It said:

(US$m) TLX delivered 56% revenue growth inclusive of 20% organic revenue growth in Precision Medicine. Group EBITDA declined by 41% to $39.5m and the company reported a statutory loss of $7.1m. Excluding non-cash revaluation charges in finance costs, adjusted NPAT ~$19.6m.

Looking ahead, the broker is feeling optimistic thanks to the company’s development pipeline. It adds:

The company will remain focussed on pipeline development for at least FY27/FY28. The priorities are development of therapy assets with the four ongoing clinical trials (prostate cancer, glioma, renal and metastatic bone) and the imaging study in prostate (BiPass) all of which are now enrolling patients, hence the next two years are expected to deliver plenty of data. Beyond 2028 there are multiple targets to pursue, hence there won’t be any easing up on R&D spend.

It was also pleased to see management guiding to solid revenue growth in FY 2026, excluding any contributions from potential approvals. Bell Potter explains:

Guidance is for FY26 revenues in the range of $950m-$970m before the impact of any new approvals. Our most recent forecast was $925m, hence the forecast is bullish and assumes ongoing market share gains and conversion of existing Illuccix clients to the higher reimbursed Gozellix product. The bottom end of the guidance is 2% ahead of the market. Our FY26 revenue forecast is unchanged at this time.

Time to buy Telix shares?

According to the note, Bell Potter has retained its buy rating on Telix shares with a reduced price target of $19.00.

Based on its current share price of $10.43, this implies potential upside of 82% for investors over the next 12 months.

Commenting on its buy recommendation, Bell Potter said:

FY25 was a challenging period by virtue to the two CRLs from the FDA and a stream of negative news flow – most recently the sudden resignation of the Chairperson. Nevertheless, the clinical programs are ongoing, and the company is well funded to continue these. We expect more of the same in CY26 minus the regulatory setbacks. The outlook for long term revenue growth remains encouraging and in the short term the guidance is not unrealistic. Short term catalysts include data readouts from Prostact Global. We expect to see the Pixclara BLA resubmitted within weeks.

The post Why Telix shares could rise 80% in a year appeared first on The Motley Fool Australia.

More reading

• Forget CSL shares, this ASX biotech stock could triple in value
• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today
• This biotech says it will turn over more than $1 billion next year. Is it undervalued?

The Lendlease Corporation Ltd (ASX: LLC) share price is focus today after the property and infrastructure group reported a statutory loss after tax of $318 million for the half year ended 31 December 2025, driven by non-cash negative investment property revaluations and impairments.

The company’s Investments, Development and Construction segment delivered EBITDA of $204 million, with a strong showing from its Australian construction pipeline and $4.7 billion in new development projects secured.

What did Lendlease report?

• Statutory loss after tax of $(318) million (HY25: $48 million profit)
• Operating profit after tax (OPAT) of $(200) million, including $87 million from Investments, Development and Construction (IDC) and $(287) million from Capital Release Unit (CRU)
• IDC segment EBITDA: $204 million; IDC earnings per stapled security of 12.6 cents
• CRU segment EBITDA: $(284) million, reflecting write downs and transaction timing
• Interim distribution of 6.2 cents per security
• Net debt reduced to $3.3 billion; statutory gearing of 25.8%

What else do investors need to know?

Lendlease’s CRU continues its capital recycling program, with $2.8 billion of asset sales announced or completed since May 2024 and a further $1.5 billion targeted in FY26. The company’s Australian construction business performed strongly, securing $4.0 billion of new work and lifting backlog revenue to $8.0 billion, up 36% on the prior period.

In the Investments segment, funds under management remained stable at $48.7 billion, with $1.8 billion raised for new vehicles and mandates. The Group highlighted improved project performance and a reduction in corporate costs, with overheads 14% lower on the prior period as efficiency and cost-out programs continue.

What did Lendlease management say?

Group Chief Executive Officer, Tony Lombardo, said:

FY26 is a transitional year, with our core operating segments performing in line with expectation. We anticipate stronger Investments, Development and Construction earnings in the second half and into FY27. The Group continues to make considerable progress on its strategy with momentum building across its core operations. Our Development and Construction pipelines remain strong, and we are seeing continued growth in investor partnering and mandate activity. Our focus remains on driving long-term value creation for our securityholders, with enhanced earnings visibility from FY27, and a material reduction of net debt through further capital recycling.

What’s next for Lendlease?

Lendlease maintains its FY26 guidance for IDC segment earnings per security at 28–34 cents, with second half earnings and transactional profits expected to be higher. No FY26 EPS guidance is provided for the CRU segment. The Group continues to prioritise strengthening its balance sheet, executing on capital recycling initiatives and further reducing net debt.

Key medium-term priorities include growing the Investments platform, restocking the Australian development pipeline, and targeting high-quality construction work. With $3.0 billion in announced or in-progress transactions, Lendlease expects enhanced earnings visibility, especially from major project completions in FY27 and FY28.

Lendlease share price snapshot

Over the past 12 months, Lendlease shares have declined 27%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post Lendlease half-year results: $318m loss, construction steady, capital recycling on track appeared first on The Motley Fool Australia.

More reading

• Greatland Resources earnings: Bumper profit and revenue after first full Telfer half
• Regis Healthcare grows revenue and cash flow in H1 FY26 earnings
• nib Group lifts 1H26 profit, keeps dividend steady
• Reece HY26 results: Profit falls despite higher sales revenue
• Chorus half-year earnings: Profit growth and higher fibre uptake

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.